What does the evidence say about Carnosine Sleep Quality Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Carnosine Sleep Quality Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Individuals with T2DM have a higher risk of mental health disorders (Arias et al. ; Deshpande et al. ; Ducat et al. ), with the prevalence of depression reported to be two‐fold higher in those with T2DM compared with the general population (Roy and Lloyd ). [Kabthymer Robel Hussen (2026); evidence level 2] - Similarly, the prevalence of depression is moderately increased in individuals with prediabetes compared with their normo‐glycaemic counterparts (Chen et al. ). [Kabthymer Robel Hussen (2026); evidence level 2] - This increased risk may be partly due to diabetes‐related distress, which affects a large proportion of this population and can contribute to depressive symptoms (Perrin et al. ). [Kabthymer Robel Hussen (2026); evidence level 2] - 2021 2023 2019 2023 2022 Globally, approximately half a billion individuals live with diabetes, with type 2 diabetes mellitus (T2DM) accounting for 90% of the disease burden (IDF ). [Kabthymer Robel Hussen (2026); evidence level 2] - The other recent systematic review and meta-analysis (Song et al.) showed that older patients living with PU experience two times higher risk of mortality than those who do not have such wounds. [Świątkiewicz Maciej (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.